Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated.

12 Mar 2015

Study finding suggests importance of individually-tailored treatment for depression

The most commonly used treatment for the over 14 million Americans who suffer from Major Depressive Disorder is anti-depressant medication. While such medications bring relief to many, current research suggests that one size may not fit all when it comes to treating depression.

12 Mar 2015

Study: Family Based Interpersonal Psychotherapy effective in treating preadolescents with depression

A recent study published in the March 2015 issue of the Journal of the American Academy of Child and Adolescent Psychiatry finds that Family Based Interpersonal Psychotherapy (FB-IPT) is more effective in treating preadolescent children with depression compared to child-centered therapy (CCT).

4 Mar 2015

Pain from social rejection lasts longer for people with untreated depression

Rejected by a person you like? Just "shake it off" and move on, as music star Taylor Swift says.

27 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Brain scans can predict therapeutic responses to talk therapy

UNC School of Medicine researchers have shown that brain scans can predict which patients with clinical depression are most likely to benefit from a specific kind of talk therapy.

4 Feb 2015

Chronic pain common in affective disorders

Patients with major depressive disorder or bipolar disorder frequently report chronic pain at multiple sites, research shows.

30 Jan 2015

Majority of Canada's homeless adults with mental illness show evidence of cognitive deficits

Nearly three-quarters of homeless adults with mental illness in Canada show evidence of cognitive deficits, such as difficulties with problem solving, learning and memory, new research has found.

27 Jan 2015

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia.

20 Jan 2015

Study highlights public health significance of depression among U.S. adolescents

A recent study published in the January 2015 issue of the Journal of the American Academy of Child and Adolescent Psychiatry underscores the important public health significance of depression among U.S. adolescents.

7 Jan 2015

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

6 Jan 2015

LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics announced today that it has entered into a strategic collaboration with Lucerne Biosciences, LLC to commercialize U.S. Patent No. 8,318,813 entitled "Method of Treating Binge Eating Disorder."

26 Dec 2014

Health promotion program reduces cardiovascular risk in obese people with serious mental illness

A health promotion program, called In SHAPE, specifically designed for people with serious mental illness, produced more fit participants and significant weight loss than a control group where participants only received a gym membership.

18 Dec 2014

Going to bed late evenings linked to repetitive negative thoughts

When you go to bed, and how long you sleep at a time, might actually make it difficult for you to stop worrying. So say Jacob Nota and Meredith Coles of Binghamton University in the US, who found that people who sleep for shorter periods of time and go to bed very late at night are often overwhelmed with more negative thoughts than those who keep more regular sleeping hours.

5 Dec 2014

UT Arlington researcher receives grant to educate Hispanic patients about depression, treatment options

A University of Texas at Arlington researcher hopes to dispel myths about depression and its treatment, as well as reduce the stigma associated with receiving mental health care among Hispanics.

27 Nov 2014

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") is pleased to announce that it has closed a brokered private placement offering (the "Brokered Offering") of special warrants for approximately C$3.7 million.

21 Nov 2014

Pathological guilt in preschool years linked to brain changes, increases risk for recurrent depression

In school-age children previously diagnosed with depression as preschoolers, a key brain region involved in emotion is smaller than in their peers who were not depressed, scientists have shown.

14 Nov 2014

Bipolar mixed episodes increase significantly under DSM-5

Using the most recent diagnostic criteria increases the prevalence of mixed features in patients with bipolar disorder more than threefold, study findings indicate.

13 Nov 2014

Scientists receive NARSAD Distinguished Investigator Grants for mental health research

The Brain & Behavior Research Foundation today announced the award of NARSAD Distinguished Investigator Grants valued at $1.5 million to 15 scientists, who are full professors or the equivalent, conducting innovative projects in diverse areas of neurobiological and behavioral research.